| Inhibition of human CYP2C19 - BioAssay Summary High throughput screening (HTS) of our compound file provided an attractive lead compound with modest P2X(7) receptor antagonist potency and high selectivity against a panel of receptors and channels, but also with high human plasma protein binding and a predicted short half-life in humans. Multi-parameter optimization was used to address the potency, physicochemical and pharmacokinetic properties which led to potent P2X(7)R antagonists with good disposition properties. Compound 33 (CE-224,535) was advanced to clinical studies for the treatment of rheumatoid arthritis. ..more |
_ | |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Target Tested Compound: Description: Title: Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535. Abstract: High throughput screening (HTS) of our compound file provided an attractive lead compound with modest P2X(7) receptor antagonist potency and high selectivity against a panel of receptors and channels, but also with high human plasma protein binding and a predicted short half-life in humans. Multi-parameter optimization was used to address the potency, physicochemical and pharmacokinetic properties which led to potent P2X(7)R antagonists with good disposition properties. Compound 33 (CE-224,535) was advanced to clinical studies for the treatment of rheumatoid arthritis. (PMID: 21565499) Categorized Comment ChEMBL Assay Type: ADMET ChEMBL Assay Data Source: Scientific Literature ChEMBL Target ID: 12912 ChEMBL target type: Target is a single protein chain Result Definitions
* Activity Concentration. Data Table (Concise) Classification
PageFrom: |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||